In the midst of the global COVID-19 pandemic, vaccination efforts have played a pivotal role in combating the virus. It’s crucial to continuously assess and analyze the impact of these vaccines on mortality rates. In this article, we delve into various datasets and correlations to understand the relationship between COVID-19 vaccination and mortality rates. Our journey through data-driven analysis will encompass safety, risk assessment, vaccine effectiveness, and the complexities of interpreting this crucial information.
Table of ContentsVaccine Trial DataUnderstanding Vaccine SafetyThe Varus DatabaseAssessing COVID-19 Mortality RiskVaccine EffectivenessAnalyzing Vaccine Trial DataData, Correlations, and ComplexityData Discrepancies and TransparencyThe Middle Ground and ComplexityGlobal CorrelationsChange in Mortality RatesConclusionTake-Home MessageFAQsRelated Articles
Vaccine Trial Data
The initial trials of COVID-19 vaccines provide important insights. However, some unusual patterns have emerged. During these trials, participants who received the vaccine reported fewer COVID-19-like symptoms. This phenomenon raises questions about the trial design and the possibility that participants altered their reporting due to their awareness of being in the vaccine group.
Understanding Vaccine Safety
The Varus Database
One of the key concerns regarding COVID-19 vaccines is their potential impact on mortality. To assess this, we turn to the Vaccine Adverse Event Reporting System (VAERS) database, which collects reports of adverse events following vaccination. It’s important to note that these reports don’t necessarily establish causation between the vaccine and mortality but provide valuable insights.
Upper Bound of Risk: VAERS data show around 14.5 thousand deaths reported after COVID-19 vaccination. However, not all of these deaths are directly caused by the vaccine, and underreporting is likely.
Lower Bound of Risk: By considering specific adverse events with known mortality rates, such as thrombosis (TTS) and myocarditis, we estimate a lower bound of risk. This approach yields around 11 micromorts, which is roughly equivalent to the risk associated with activities like swimming or playing football.
Validation from Other Sources: Data from different countries and studies in Japan support this lower bound estimate, lending credibility to its reliability.
Assessing COVID-19 Mortality Risk
To make an informed assessment of the COVID-19 vaccine’s impact on mortality, we must compare it to the actual risk posed by the virus itself.
Age Matters: COVID-19’s mortality risk varies significantly with age. For individuals in their 30s to 40s, the case mortality rate is around 600 micromorts. However, this number requires adjustments.
Infection Fatality Rate: We must consider the infection fatality rate, accounting for undiagnosed cases. Assuming a seven-fold higher infection rate than reported cases, we arrive at a more accurate estimate.
False Positives: The accuracy of COVID-19 tests introduces another layer of complexity. Accounting for false positives is crucial, as they can skew mortality statistics.
Prior Infections: As a large portion of the population may have already been infected with COVID-19, their risk of reinfection and subsequent mortality is significantly reduced.
When all these factors are considered, the mortality risk for individuals in their 30s to 40s drops to around 2 micromorts, making it substantially lower than the lower bound of vaccine-related risk.
Vaccine Effectiveness
Vaccine effectiveness is the other critical aspect to consider when evaluating the overall impact of COVID-19 vaccines. We must ascertain if vaccines deliver on their promise to reduce mortality and infection rates.
Analyzing Vaccine Trial Data
One perplexing observation arises from the vaccine trial data. The experimental group, which received the vaccine,
Discover more from Randy Bock MD PC
Subscribe to get the latest posts sent to your email.
